Heart benefits from GLP-1 meds fade after stopping, large study finds
A large BMJ Medicine study using Veterans Health Administration records found that cardiovascular benefits from GLP-1 injections fade quickly after stopping the drugs: risk of heart attack, stroke and related events rises by about 4% at six months, 14% at one year, and 22% by the second year off therapy, approaching pre-treatment levels. The findings suggest ongoing GLP-1 treatment is needed to maintain heart benefits, with the advantage appearing to be partly weight-independent, as seen in related obesity trials.
